Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.69 |
| ▸ | NPC1 | O15118 | 7/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.69 |
| ▸ | CASP1 | P29466 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.62 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 5/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28735058 | 0.98 | NPC1 (0.68) | RAB9ANPC1SMN1; SMN2CASP1TSHR | |
| SCHEMBL7209064 | 0.95 | RAB9A (0.76) | RAB9ANPC1SMN1; SMN2CASP1TSHR | |
| SCHEMBL12411578 | 0.89 | RAB9A (0.69) | RAB9ANPC1SMN1; SMN2CASP1TSHR | |
| SCHEMBL22441355 | 0.87 | RAB9A (0.91) | RAB9ANPC1SMN1; SMN2CASP1TSHR | |
| SCHEMBL8600999 | 0.86 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2CASP1TSHR | |
| SCHEMBL7564852 | 0.85 | RAB9A (0.79) | RAB9ANPC1SMN1; SMN2CASP1TSHR | |
| SCHEMBL8076542 | 0.84 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2CASP1TSHR | |
| SCHEMBL21059194 | 0.84 | RAB9A (0.64) | RAB9ANPC1SMN1; SMN2CASP1TSHR | |
| SCHEMBL7995030 | 0.84 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2CASP1TSHR | |
| SCHEMBL10599124 | 0.84 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2CASP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3931183-B1 | COMPOUNDS WITH FERROPTOSIS INDUCING ACTIVITY AND METHODS OF THEIR USE | FERRO THERAPEUTICS INC (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-114008024-A | Compounds having iron death inducing activity and methods of using the same | 费罗治疗公司 | 2022-02-01 | — | — | CN | disclosed |
| US-20220002280-A1 | COMPOUNDS AND METHODS OF USE | FERRO THERAPEUTICS INC (US) | 2022-01-06 | — | — | US | disclosed |
| EP-3931183-A1 | COMPOUNDS WITH FERROPTOSIS INDUCING ACTIVITY AND METHODS OF THEIR USE | Ferro Therapeutics, Inc. (US) | 2022-01-05 | — | — | EP | disclosed |
| US-11040964-B2 | Compounds and methods of use | Ferro Therapeutics, Inc. (US) | 2021-06-22 | — | — | US | disclosed |
| US-11040964-B2 | Compounds and methods of use | Ferro Therapeutics, Inc. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200299283-A1 | COMPOUNDS AND METHODS OF USE | BRIDGEBIO PHARMA, INC. | 2020-09-24 | — | — | US | disclosed |
| US-20200299283-A1 | COMPOUNDS AND METHODS OF USE | BRIDGEBIO PHARMA, INC. | 2020-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002280-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, GPX4, GPX1 | RAB9A 2446/4885NPC1 363/4885SMN1; SMN2 2416/4885 |
| US-20200299283-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, GPX4, GPX1 | RAB9A 2446/4885NPC1 363/4885SMN1; SMN2 2416/4885 |
| US-11040964-B2 | Compounds and methods of use | AIFM2, GPX4, GPX1 | RAB9A 2446/4885NPC1 363/4885SMN1; SMN2 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.